Literature DB >> 2515823

[Intravenous thrombolysis with tissue plasminogen activator (rt-PA) at the prehospital phase of acute myocardial infarction. Apropos of 49 cases].

P Cazaux1, G Leclercq, A Vahanian, P L Michel, J M Soulas, P Barriot, P Sauval, M Cupa, C Lapandry, J Conard.   

Abstract

In acute myocardial infarction, the earlier intravenous thrombolysis is performed the more effective its action. Pre-hospital intravenous thrombolysis with 100 mg rt-PA was carried out in 49 patients within 3 hours of myocardial infarction. Male preponderance was conspicuous with 44 men (92%) and only 5 women (8%). Mean age was 50.2 +/- 8 years. The infarction was inferior in 48% of the cases. Out of the 49 thrombolyses performed by the mobile intensive care unit, 3 were discontinued on admission (2 diagnostic errors, 1 external heart massage). The time gained by pre-hospital thrombolysis was 52 +/- 25 minutes. There were few complications of thrombolysis: blood effusion at the site of puncture occurred in 4 cases (9%) and haematemesis in 1 case (2%). No cerebral or lethal haemorrhage was observed. Major complications of MI were seldom encountered at the pre-hospital phase: 1 patient died of extensive anterior necrosis with left ventricular dysfunction, and 2 had reversible ventricular fibrillation before treatment was initiated. There was no haemorrhagic complication. The earlier the patient was treated the lower the mortality and morbidity rates. Pre-hospital thrombolysis therefore seems to be feasible when performed by a mobile intensive care unit, and it represents an important gain of time.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2515823

Source DB:  PubMed          Journal:  Arch Mal Coeur Vaiss        ISSN: 0003-9683


  2 in total

1.  Feasibility and long term outcome of home vs hospital initiated thrombolysis.

Authors:  B McAleer; M P S Varma
Journal:  Ir J Med Sci       Date:  2006 Oct-Dec       Impact factor: 1.568

2.  Prehospital thrombolysis in a rural community: short- and long-term survival.

Authors:  B McAleer; B Ruane; E Burke; M Cathcart; A Costello; G Dalton; J R Williams; M P Varma
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.